| Literature DB >> 27565571 |
Eugene Han1,2, Gyuri Kim1,2, Namki Hong1,2, Yong-Ho Lee3,4, Dong Woo Kim5, Hyun Joon Shin6,7, Byung-Wan Lee1,2,8, Eun Seok Kang1,2,8, In-Kyu Lee9, Bong-Soo Cha1,2,8.
Abstract
BACKGROUND: Acid-base imbalance has been reported to increase incidence of hypertension and diabetes. However, the association between diet-induced acid load and cardiovascular disease (CVD) risk in the general population has not been fully investigated.Entities:
Keywords: Atherosclerosis; Diet; Epidemiology; Risk factors
Mesh:
Substances:
Year: 2016 PMID: 27565571 PMCID: PMC5002186 DOI: 10.1186/s12933-016-0436-z
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Fig. 1The flow diagram of subject inclusion and exclusion in the Korean National Health and Nutrition Examination Surveys (KNHANES IV and V)
Baseline characteristics of study population by categories of PRAL
| Tertiles of dietary PRAL (mEq/day) | P value* | |||
|---|---|---|---|---|
| T1 (n = 3859) | T2 (n = 3540) | T3 (n = 4202) | ||
| PRAL (mEq/d)a | −21.8 (−199.8 ~ −7.5) | −2.9‡ (−11.3 ~ 8.2) | 11.2‡ (−10.4 ~ 181.4) | <0.001 |
| DAL (mEq/d) | 11.1 ± 20.8 | 35.9 ± 6.5‡ | 53.4 ± 14.6‡ | <0.001 |
| Magnesium (mg/d) | 388.0 ± 186.4 | 278.1 ± 139.4‡ | 307.8 ± 177.2‡ | <0.001 |
| Age (year) | 56.2 ± 10.3 | 57.1 ± 11.0‡ | 56.8 ± 11.2‡ | 0.001 |
| Male (%) | 41.4 | 41.3 | 41.8 | 0.881 |
| Waist circumference (cm) | 82.7 ± 9.0 | 82.5 ± 9.2 | 82.9 ± 9.3 | 0.255 |
| BMI (kg/m2) | 24.1 ± 3.0 | 23.9 ± 3.1‡ | 24.0 ± 3.1 | 0.041 |
| Systolic blood pressure (mmHg) | 120.4 ± 17.2 | 122.1 ± 18.0‡ | 122.2 ± 17.6‡ | <0.001 |
| Diastolic blood pressure (mmHg) | 76.3 ± 10.1 | 76.8 ± 10.6 | 77.2 ± 10.5‡ | 0.001 |
| Fasting plasma glucose (mg/dL) | 101.4 ± 27.5 | 100.5 ± 23.3 | 100.6 ± 24.9 | 0.213 |
| Total cholesterol (mg/dL)b | 193.2 ± 36.1 | 194.1 ± 36.7 | 194.3 ± 36.5 | 0.436 |
| HDL cholesterol (mg/dL)b | 51.1 ± 12.3 | 51.1 ± 12.6 | 51.2 ± 12.5 | 0.842 |
| Triglycerides (mg/dL)b | 138.8 ± 102.7 | 145.5 ± 119.8‡ | 144.7 ± 113.5‡ | 0.004 |
| LDL cholesterol (mg/dL)b | 119.0 ± 32.4 | 119.2 ± 32.6 | 119.0 ± 32.3 | 0.043 |
| Creatinine (mg/dL) | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.3 | 0.903 |
| eGFR (mL/min/1.73 m2) | 88.3 ± 14.9 | 87.9 ± 15.0 | 88.5 ± 15.5 | 0.193 |
| Insulin (ųU/mL)b | 9.8 ± 5.2 | 9.8 ± 5.9 | 10.0 ± 6.5 | 0.807 |
| HOMA-IRb | 2.5 ± 1.9 | 2.5 ± 1.8 | 2.5 ± 2.5 | 0.962 |
| Urine pH | 5.8 ± 0.9 | 5.7 ± 0.9 | 5.7 ± 0.8‡ | 0.013 |
| Heavy drink (%) | 12.3 | 14.1 | 17.0‡ | <0.001 |
| Current smoking (%) | 15.4 | 17.8‡ | 20.0‡ | <0.001 |
| Exercise (%) | 28.3 | 24.6‡ | 24.6‡ | <0.001 |
| Hypertension (%) | 34.4 | 37.9‡ | 38.5‡ | <0.001 |
| IFG/Diabetes (%) | 23.3/13.4 | 24.2/13.4 | 25.0/12.7 | 0.427 |
| Metabolic syndrome (%) | 37.1 | 38.8 | 40.2‡ | 0.014 |
| Chronic kidney disease (%) | 3.8 | 4.3 | 4.5 | 0.263 |
| Region (Metro/City/Rural, %) | 43.3/30.2/26.5 | 42.3/31.5/26.3 | 41.7/30.2/28.1 | 0.237 |
| Family history of cardio- or cerebro-vascular disease (%) | 6.6 | 6.3 | 6.7 | 0.811 |
PRAL potential renal acid load; DAL dietary acid load; BMI body mass index; HDL cholesterol, high density lipoprotein cholesterol; LDL cholesterol, low density lipoprotein cholesterol; eGFR estimated glomerular filtration rate; HOMA-IR homeostasis model assessment of insulin resistance; IFG impaired fasting glucose
‡P < 0.05 by post hoc analyses when compared with lowest tertiles
*Chi square tests for qualitative variables and ANOVA tests for quantitative variables
aValues are medians per tertile
bLog-transformed
Baseline characteristics of study population by categories of DAL
| Tertiles of dietary DAL (mEq/day) | P value* | |||
|---|---|---|---|---|
| T1 (n = 3900) | T2 (n = 3839) | T3 (n = 3826) | ||
| DAL (mEq/d)a | 16.9 (−165.5 ~ 33.9) | 36.1‡ (25.9 ~ 48.5) | 51.9‡ (39.3 ~ 221.1) | <0.001 |
| PRAL (mEq/d) | −27.5 ± 20.5 | −2.2 ± 5.3‡ | 15.4 ± 13.4‡ | <0.001 |
| Magnesium (mg/d) | 381.4 ± 187.5 | 284.0 ± 146.0‡ | 310.4 ± 177.0‡ | <0.001 |
| Age (year) | 56.8 ± 10.5 | 57.4 ± 11.1‡ | 55.9 ± 10.9‡ | <0.001 |
| Male (%) | 40.8 | 40.5 | 43.0 | 0.062 |
| Waist circumference (cm) | 81.7 ± 8.8 | 82.1 ± 9.1 | 84.4 ± 9.4‡ | <0.001 |
| BMI (kg/m2) | 23.7 ± 2.9 | 23.7 ± 3.1 | 24.5 ± 3.2‡ | <0.001 |
| Systolic blood pressure (mmHg) | 120.5 ± 17.3 | 122.2 ± 18.3‡ | 121.9 ± 17.2‡ | <0.001 |
| Diastolic blood pressure (mmHg) | 76.1 ± 10.1 | 76.6 ± 10.5 | 77.6 ± 10.5‡ | <0.001 |
| Fasting plasma glucose (mg/dL) | 101.3 ± 27.7 | 100.4 ± 24.5 | 100.9 ± 24.5 | 0.268 |
| Total cholesterol (mg/dL)b | 193.0 ± 36.2 | 194.2 ± 36.8 | 194.5 ± 36.2 | 0.146 |
| HDL cholesterol (mg/dL)b | 51.5 ± 12.4 | 51.3 ± 12.6 | 50.7 ± 12.3‡ | 0.031 |
| Triglycerides (mg/dL)b | 137.4 ± 110.9 | 142.8 ± 106.1‡ | 148.7 ± 118.9‡ | <0.001 |
| LDL cholesterol (mg/dL)b | 118.7 ± 32.5 | 119.4 ± 32.8 | 119.0 ± 32.0 | 0.613 |
| Creatinine (mg/dL) | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.9 ± 0.3 | 0.085 |
| GFR, EPI (mL/min/1.73 m2) | 88.3 ± 14.9 | 87.7 ± 15.1 | 88.8 ± 15.5 | 0.011 |
| Insulin (μU/mL)b | 9.5 ± 4.8 | 9.8 ± 5.8 | 10.3 ± 6.7‡ | <0.001 |
| HOMA-IRb | 2.4 ± 1.8 | 2.5 ± 1.8 | 2.6 ± 2.6‡ | <0.001 |
| Urine pH | 5.8 ± 0.9 | 5.7 ± 0.9 | 5.7 ± 0.8‡ | 0.001 |
| Heavy drink (%) | 12.1 | 13.9 | 17.8‡ | <0.001 |
| Current smoking (%) | 15.7 | 17.4 | 20.3‡ | <0.001 |
| Exercise (%) | 27.9 | 24.4‡ | 25.3 | <0.001 |
| Hypertension (%) | 34.4 | 37.6‡ | 38.7‡ | <0.001 |
| IFG/diabetes (%) | 22.8/13.3 | 24.0/13.2 | 25.9/13.0 | 0.918 |
| Metabolic syndrome (%) | 35.1 | 38.1‡ | 43.1‡ | <0.001 |
| Chronic kidney disease (%) | 3.8 | 4.5 | 4.2 | 0.376 |
| Region (Metro/City/rural, %) | 42.5/30.2/27.3 | 43.2/30.6/26.3 | 41.6/30.9/27.5 | 0.613 |
| Family history of cardio- or cerebro-vascular disease (%) | 6.5 | 6.6 | 6.6 | 0.984 |
‡P < 0.05 by post hoc analyses when compared with lowest tertiles
*Chi square tests for qualitative variables and ANOVA tests for quantitative variables
PRAL potential renal acid load; DAL dietary acid load; BMI body mass index; HDL cholesterol, high density lipoprotein cholesterol; LDL cholesterol, low density lipoprotein cholesterol; eGFR estimated glomerular filtration rate; HOMA-IR homeostasis model assessment of insulin resistance; IFG impaired fasting glucose
aValues are medians per tertile
bLog-transformed
Fig. 2Differences in CVD risk according to PRAL tertiles. a Average ACC/AHA ASCVD 10 year risk scores. b Average ACC/AHA ASCVD 10 year risk scores in age groups. c Proportion of individuals with high ACC/AHA ASCVD 10 year risk (>10 %). d Proportion of individuals with high ACC/AHA ASCVD 10 year risk (>10 %) in age groups. Mean ± standard errors, *P < 0.05, **P < 0.001
Fig. 3Differences in the CVD risk according to PRAL tertiles. a Average Framingham 10 year risk scores. b Average Framingham 10 year risk scores in age groups. c Proportion of individuals with high Framingham 10 year risk (>20 %). d Proportion of individuals with high Framingham 10 year risk (>20 %) in age groups. Mean ± standard errors, *P < 0.05, **P < 0.001
Fig. 4Differences in the CVD risk according to DAL tertiles. a Average ACC/AHA ASCVD 10 year risk scores. b Average ACC/AHA ASCVD 10 year risk scores in age groups. c Proportion of individuals with high ACC/AHA ASCVD 10 year risk (>10 %). d Proportion of individuals with high ACC/AHA ASCVD 10 year risk (>10 %) in age groups. Mean ± standard errors, *P < 0.05, **P < 0.001
Fig. 5The proportion of individuals with high ACC/AHA ASCVD 10 year risk (>10 %) stratified by age groups. a Diet-induced acid load defined by PRAL score. b Diet-induced acid load defined by DAL score. Dark and light boxes indicate the high-score group and the lowest score group, respectively. *P < 0.05, **P < 0.001
Fig. 6Difference in CVD risk according to PRAL scores, stratified by metabolic status and physical activity. a Proportion of individuals with high ACC/AHA ASCVD 10 year risk stratified by overweight defined as BMI ≥23 kg/m2, b regular exercise, c HOMA-IR with a cutoff point of 2.5, and d sarcopenia defined as ASM/BMI definition. The data are presented as OR with 95 % CI, NS non-significance; *P < 0.05, **P < 0.001
Fig. 7Proportion of individuals with high ACC/AHA ASCVD 10 year risk according to sarcopenic status. a ASM/height2 definition. b ASM/weight definition. The data are presented as OR with 95 % CI, NS non-significance; *P < 0.05, **P < 0.001
Odds ratio and 95 % confidential interval of high ASCVD risk (>10 % 2013 ACC/AHA score) according to PRAL tertiles in adults
| Lowest tertile | Second tertile | Highest tertile | |
|---|---|---|---|
| Crude | 1 (referent) | 1.27 (1.15–1.40) | 1.23 (1.22–1.35) |
| Model 1 | 1 (referent) | 1.29 (1.11–1.51) | 1.18 (1.02–1.36) |
| Model 2 | 1 (referent) | 1.28 (1.10–1.50) | 1.17 (1.01–1.35) |
| Model 3 | 1 (referent) | 1.31 (1.09–1.58) | 1.20 (1.01–1.43) |
Model 1: adjusted for age (per 5 years), and sex
Model 2: adjusted for age (per 5 years), sex, exercise, and family history of cardio- and cerebro-vascular disease
Model 3: adjusted for age (per 5 years), sex, exercise, family history of cardio- and cerebro-vascular disease, diabetes, hypertension, LDL cholesterol, eGFR, and urine pH
ASCVD 10 year atherosclerotic vascular disease; PRAL potential renal acid load; eGFR estimated glomerular filtration rate; LDL cholesterol; low density lipoprotein cholesterol
Odds ratio and 95 % confidential interval of high ASCVD risk (>10 % 2013 ACC/AHA score) according to DAL tertiles in adults
| Lowest tertile | Second tertile | Highest tertile | |
|---|---|---|---|
| Crude | 1 (referent) | 1.21 (1.10–1.33) | 1.00 (0.90–1.09) |
| Model 1 | 1 (referent) | 1.24 (1.07–1.44) | 1.16 (1.00–1.35) |
| Model 2 | 1 (referent) | 1.23 (1.06–1.43) | 1.15 (0.99–1.34) |
| Model 3 | 1 (referent) | 1.25 (1.04–1.46) | 1.07 (0.89–1.28) |
Model 1: adjusted for age (per 5 years), and sex
Model 2: adjusted for age (per 5 years), sex, exercise, and family history of cardio- and cerebro-vascular disease
Model 3: adjusted for age (per 5 years), sex, exercise, family history of cardio- and cerebro-vascular disease, diabetes, hypertension, LDL cholesterol, eGFR, and urine pH
ASCVD 10 year atherosclerotic vascular disease; DAL dietary acid load; eGFR estimated glomerular filtration rate; LDL cholesterol; low density lipoprotein cholesterol
Odds ratio and 95 % confidential interval of high Framingham 10 year risk (>20 %) according to PRAL tertiles in adults
| Lowest tertile | Second tertile | Highest tertile | |
|---|---|---|---|
| Crude | 1 (referent) | 1.22 (1.10–1.36) | 1.18 (1.06–1.31) |
| Model 1 | 1 (referent) | 1.19 (1.03–1.36) | 1.16 (1.01–1.32) |
| Model 2 | 1 (referent) | 1.18 (1.03–1.36) | 1.15 (1.01–1.31) |
| Model 3 | 1 (referent) | 1.25 (1.05–1.49) | 1.19 (1.01–1.41) |
Model 1: adjusted for age (per 5 years), and sex
Model 2: adjusted for age (per 5 years), sex, exercise, and family history of cardio- and cerebro-vascular disease
Model 3: adjusted for age (per 5 years), sex, exercise, family history of cardio- and cerebro-vascular disease, diabetes, hypertension, LDL cholesterol, eGFR, and urine pH
ASCVD 10 year atherosclerotic vascular disease; PRAL potential renal acid load; eGFR estimated glomerular filtration rate; LDL cholesterol; low density lipoprotein cholesterol